Clinical Trial Update: Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fasiglifam (TAK-875) to placebo and sitagliptin, added to metformin, in type 2 diabetes; the study was terminated and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)
• fasiglifam (fasiglifam)
• metformin (metformin)

Snippet

Sponsor: Takeda | Conditions: Glycemic Control | Phase 3 | Status: TERMINATED | Results posted: 2016-06-02